Quantum Biopharma (QNTM) Expected to Post Quarterly Earnings on Friday

Quantum Biopharma (NASDAQ:QNTM) is anticipated to release its resultson Friday, November 6th. Analysts expect the company to post earnings of ($0.50) per share for the quarter.

Quantum Biopharma (NASDAQ:QNTM) last announced its earnings results on Thursday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06).

Quantum Biopharma Stock Down 2.2%

Quantum Biopharma stock opened at $2.21 on Wednesday. Quantum Biopharma has a twelve month low of $2.07 and a twelve month high of $12.42. The stock has a 50 day moving average of $3.07 and a two-hundred day moving average of $3.85.

Analyst Ratings Changes

Several brokerages have commented on QNTM. Weiss Ratings lowered shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Wall Street Zen raised shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, Rodman & Renshaw started coverage on shares of Quantum Biopharma in a report on Monday, August 31st. They issued a “buy” rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

Quantum Biopharma Company Profile

Quantum BioPharma Ltd. is a biotechnology company focused on developing treatments for neurodegenerative and neurological disorders. Its lead drug candidate, Lucid-21-302, also known as Lucid-MS, is an orally administered small molecule being developed as a potential therapy for multiple sclerosis. The company is investigating the compound’s ability to protect nerve cells and promote remyelination, or the repair of damaged myelin.

Quantum BioPharma is also pursuing additional applications for its drug-development platform, including potential treatments for other neurodegenerative and mental health conditions.